Peer-Reviewed Case Study Shows 52% Tumor Activity Reduction with RenovoRx's TAMP™ in Pancreatic Cancer
RNXT sits 26% above its 52-week low of $0.701.
Summary
RenovoRx highlighted a peer-reviewed case study published in *Radiology Case Reports* supporting its TAMP™ system and RenovoCath for intra-arterial gemcitabine delivery in locally advanced pancreatic cancer. The study detailed a patient who experienced a 52% reduction in tumor metabolic activity after treatment. This publication adds to the growing body of evidence for RenovoRx's targeted therapy platform, following recent positive updates on its Phase III TIGeR-PaC clinical trial progress and promising pharmacokinetic data from a sub-study in May. For a small biotech, this external, peer-reviewed validation is important for demonstrating the efficacy and procedural flexibility of its core technology.
At the time of this announcement, RNXT was trading at $0.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3M. The 52-week trading range was $0.70 to $1.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.